DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Single-round viral replication assay are 290

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_6577	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6578	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6579	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6580	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6581	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6582	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6583	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6584	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6585	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6586	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6587	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6588	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6589	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6590	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6591	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6592	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6593	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6594	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6595	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6596	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6597	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6598	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6599	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6600	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6601	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6602	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6603	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6604	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6605	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6606	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6607	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6608	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6609	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6610	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6611	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6612	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6613	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6614	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6615	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6616	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6617	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6618	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6619	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6620	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6621	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6622	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6623	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6624	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6625	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6626	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6627	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6628	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6629	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6630	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6631	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6632	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6633	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6634	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6635	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6636	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6637	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6638	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6639	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6640	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6641	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6642	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6643	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6644	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6645	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6646	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6647	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6648	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6649	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6650	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6651	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6652	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6653	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6654	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6655	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6656	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6657	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6658	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6659	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6660	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6661	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6662	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6663	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6664	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6665	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6666	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6667	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6668	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6669	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6670	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6671	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6672	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6673	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6674	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6675	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6676	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6677	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6678	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6679	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6680	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6681	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6682	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6683	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6684	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6685	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6686	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6687	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6688	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6689	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6690	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6691	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6692	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6693	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6694	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6695	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6696	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6697	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6698	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6699	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6700	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6701	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6702	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6703	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6704	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6705	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6706	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6707	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6708	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6709	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6710	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6711	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6712	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6713	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6714	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6715	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6716	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6717	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6718	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6719	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6720	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6721	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6722	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6723	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6724	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6725	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6726	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6727	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6728	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6729	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6730	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6731	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6732	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6733	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6734	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6735	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6736	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6737	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6738	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6739	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6740	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6741	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6742	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6743	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6744	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6745	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6746	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6747	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6748	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6749	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6750	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6751	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6752	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6753	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6754	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6755	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6756	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6757	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6758	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6759	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6760	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6761	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6762	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6763	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6764	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6765	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6766	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6767	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6768	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6769	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6770	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6771	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6772	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6773	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6774	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6775	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6776	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6777	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6778	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6779	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6780	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6781	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6782	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6783	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6784	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6785	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6786	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6787	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6788	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6789	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6790	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6791	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6792	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6793	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6794	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6795	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6796	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6797	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6798	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6799	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6800	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6801	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6802	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6803	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6804	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6805	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6806	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6807	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6808	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6809	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6810	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6811	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6812	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6813	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6814	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6815	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6816	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6817	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6818	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6819	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6820	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6821	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6822	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6823	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6824	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6825	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6826	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6827	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6828	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6829	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6830	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6831	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6832	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6833	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6834	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6835	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6836	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6837	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6838	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6839	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6840	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6841	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6842	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6843	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6844	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6845	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6846	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6847	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6848	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6849	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6850	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6851	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6852	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6853	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6854	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6855	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6856	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6857	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6858	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6859	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6860	Cabotegravir	Antiviral	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Phase I	29769116
DrugRepV_6861	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6862	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6863	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6864	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6865	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6866	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116